NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totaling 1,861 shares, a drop of 30.4% from the November 30th total of 2,672 shares. Based on an average daily volume of 369 shares, the days-to-cover ratio is presently 5.0 days. Based on an average daily volume of 369 shares, the days-to-cover ratio is presently 5.0 days.
NewAmsterdam Pharma Price Performance
Shares of NASDAQ:NAMSW traded up $0.40 during trading on Monday, hitting $23.90. The company had a trading volume of 535 shares, compared to its average volume of 4,361. The company has a fifty day simple moving average of $26.26 and a two-hundred day simple moving average of $18.06. NewAmsterdam Pharma has a one year low of $5.45 and a one year high of $29.99.
Hedge Funds Weigh In On NewAmsterdam Pharma
A hedge fund recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC boosted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 245,000 shares of the company’s stock after purchasing an additional 3,043 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent filing with the Securities & Exchange Commission.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- Do not delete, read immediately
- How the Rich Retire
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- How Long Will $1M Last in Retirement?
- [No Brainer Gold Play]: “Show me a better investment.”
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
